סודיום כלוריד % 0.9 לעירוי לתוך הוריד BP Ισραήλ - Εβραϊκά - Ministry of Health

סודיום כלוריד % 0.9 לעירוי לתוך הוריד bp

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

סנדוסטטין 30 מג LAR Ισραήλ - Εβραϊκά - Ministry of Health

סנדוסטטין 30 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  20 מג LAR Ισραήλ - Εβραϊκά - Ministry of Health

סנדוסטטין 20 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  10 מג LAR Ισραήλ - Εβραϊκά - Ministry of Health

סנדוסטטין 10 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סלברול קרם Ισραήλ - Εβραϊκά - Ministry of Health

סלברול קרם

teva israel ltd - sulphadiazine silver - קרם - sulphadiazine silver 1 % - silver sulfadiazine - silver sulfadiazine - treatment of infected burn wounds, leg ulcers and pressure sores.

ונטולין תמיסה לשאיפה Ισραήλ - Εβραϊκά - Ministry of Health

ונטולין תמיסה לשאיפה

glaxo smith kline (israel) ltd - salbutamol as sulfate - solution for inhalation - salbutamol as sulfate 5 mg/ml - selective beta-2 adrenoreceptor agonists - treatment of severe acute asthma (status asthmaticus) and other forms of bronchospasm.

קו-דיובאן 8012.5 מג טבליות מצופות Ισραήλ - Εβραϊκά - Ministry of Health

קו-דיובאן 8012.5 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

קו-דיובאן 16012.5 מג טבליות מצופות Ισραήλ - Εβραϊκά - Ministry of Health

קו-דיובאן 16012.5 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

קו-דיובאן 16025 מג טבליות מצופות Ισραήλ - Εβραϊκά - Ministry of Health

קו-דיובאן 16025 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

טייקרב Ισραήλ - Εβραϊκά - Ministry of Health

טייקרב

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.